Tema Etfs LLC Purchases New Stake in Merus N.V. $MRUS

Tema Etfs LLC acquired a new position in Merus N.V. (NASDAQ:MRUS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 51,215 shares of the biotechnology company’s stock, valued at approximately $2,694,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its position in shares of Merus by 34.9% during the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company’s stock valued at $198,588,000 after acquiring an additional 1,220,519 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in shares of Merus by 99.4% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company’s stock worth $141,831,000 after purchasing an additional 1,679,777 shares during the period. Westfield Capital Management Co. LP lifted its stake in Merus by 36.0% in the second quarter. Westfield Capital Management Co. LP now owns 2,042,388 shares of the biotechnology company’s stock valued at $107,430,000 after purchasing an additional 541,168 shares during the last quarter. Woodline Partners LP lifted its stake in Merus by 17.8% in the first quarter. Woodline Partners LP now owns 1,400,171 shares of the biotechnology company’s stock valued at $58,933,000 after purchasing an additional 211,653 shares during the last quarter. Finally, Siren L.L.C. grew its holdings in Merus by 33.0% during the first quarter. Siren L.L.C. now owns 1,043,467 shares of the biotechnology company’s stock valued at $43,920,000 after purchasing an additional 259,055 shares during the period. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

Merus Stock Performance

NASDAQ:MRUS opened at $96.22 on Friday. The business’s fifty day moving average is $94.62 and its 200 day moving average is $72.27. The firm has a market cap of $7.30 billion, a price-to-earnings ratio of -18.15 and a beta of 1.06. Merus N.V. has a 52-week low of $33.19 and a 52-week high of $96.28.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MRUS. Leerink Partners reissued a “market perform” rating and issued a $97.00 target price (up from $95.00) on shares of Merus in a research report on Monday, October 6th. William Blair lowered Merus from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Alliance Global Partners started coverage on Merus in a research note on Monday, August 25th. They issued a “buy” rating and a $90.00 price objective on the stock. Leerink Partnrs downgraded shares of Merus from a “strong-buy” rating to a “hold” rating in a report on Sunday, October 5th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $97.00 target price (up previously from $95.00) on shares of Merus in a research report on Monday, September 29th. Three research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $93.56.

Insider Buying and Selling at Merus

In other news, VP Harry Shuman sold 8,300 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $95.92, for a total transaction of $796,136.00. Following the sale, the vice president directly owned 11,002 shares in the company, valued at $1,055,311.84. This represents a 43.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 3.70% of the stock is currently owned by corporate insiders.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.